Evogene Ltd. (NASDAQ: EVGN) announced completion of a phase 1 clinical study of BMC128, a live bacterial product developed by ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE